491 related articles for article (PubMed ID: 16541751)
1. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
[TBL] [Abstract][Full Text] [Related]
2. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
Psaty BM; Furberg CD; Ray WA; Weiss NS
JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Jamal SM; Eisenberg MJ; Christopoulos S
Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
[TBL] [Abstract][Full Text] [Related]
5. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
Jones PH; Davidson MH
Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
[TBL] [Abstract][Full Text] [Related]
6. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
[TBL] [Abstract][Full Text] [Related]
7. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
McAdams M; Staffa J; Dal Pan G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
[TBL] [Abstract][Full Text] [Related]
8. [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].
Sirvent AE; Cabezuelo JB; Enríquez R; Amorós F; González C; Reyes A
Nefrologia; 2001; 21(5):497-500. PubMed ID: 11795020
[TBL] [Abstract][Full Text] [Related]
9. Baycol withdrawn from market.
SoRelle R
Circulation; 2001 Aug; 104(8):E9015-6. PubMed ID: 11521677
[No Abstract] [Full Text] [Related]
10. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
Kind AH; Zakowski LJ; McBride PE
WMJ; 2002; 101(7):53-6. PubMed ID: 12426921
[TBL] [Abstract][Full Text] [Related]
11. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
Ozdemir O; Boran M; Gökçe V; Uzun Y; Koçak B; Korkmaz S
Angiology; 2000 Aug; 51(8):695-7. PubMed ID: 10959522
[TBL] [Abstract][Full Text] [Related]
12. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".
Piorkowski JD
JAMA; 2004 Dec; 292(21):2655-7; discussion 2658-9. PubMed ID: 15572725
[No Abstract] [Full Text] [Related]
13. Bayer pulls cerivastatin (Baycol) from market.
Wooltorton E
CMAJ; 2001 Sep; 165(5):632. PubMed ID: 11563216
[No Abstract] [Full Text] [Related]
14. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
[TBL] [Abstract][Full Text] [Related]
15. The cerivastatin withdrawal crisis: a "post-mortem" analysis.
Maggini M; Raschetti R; Traversa G; Bianchi C; Caffari B; Da Cas R; Panei P
Health Policy; 2004 Aug; 69(2):151-7. PubMed ID: 15212862
[TBL] [Abstract][Full Text] [Related]
16. Statin safety: an appraisal from the adverse event reporting system.
Davidson MH; Clark JA; Glass LM; Kanumalla A
Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327
[TBL] [Abstract][Full Text] [Related]
17. [Myotoxicity and rhabdomyolisis due to statins].
Banga JD
Ned Tijdschr Geneeskd; 2001 Dec; 145(49):2371-6. PubMed ID: 11770264
[TBL] [Abstract][Full Text] [Related]
18. Statin safety: lessons from new drug applications for marketed statins.
Jacobson TA
Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
[TBL] [Abstract][Full Text] [Related]
19. [Safety profile of statins].
Prieto JC
Rev Med Chil; 2001 Nov; 129(11):1237-40. PubMed ID: 11836874
[TBL] [Abstract][Full Text] [Related]
20. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen.
Marsà Carretero M; Alos Manrique C; Valles Callol JA
Br J Gen Pract; 2002 Mar; 52(476):235-6. PubMed ID: 12030671
[No Abstract] [Full Text] [Related]
[Next] [New Search]
